These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
332 related articles for article (PubMed ID: 25018629)
1. Roflumilast and dyspnea in patients with moderate to very severe chronic obstructive pulmonary disease: a pooled analysis of four clinical trials. Rennard SI; Sun SX; Tourkodimitris S; Rowe P; Goehring UM; Bredenbröker D; Calverley PM Int J Chron Obstruct Pulmon Dis; 2014; 9():657-73. PubMed ID: 25018629 [TBL] [Abstract][Full Text] [Related]
2. Reduction of exacerbations by the PDE4 inhibitor roflumilast--the importance of defining different subsets of patients with COPD. Rennard SI; Calverley PM; Goehring UM; Bredenbröker D; Martinez FJ Respir Res; 2011 Jan; 12(1):18. PubMed ID: 21272339 [TBL] [Abstract][Full Text] [Related]
3. Roflumilast: a phosphodiesterase-4 inhibitor for the treatment of severe chronic obstructive pulmonary disease. Pinner NA; Hamilton LA; Hughes A Clin Ther; 2012 Jan; 34(1):56-66. PubMed ID: 22284994 [TBL] [Abstract][Full Text] [Related]
4. Potential treatment benefits and safety of roflumilast in COPD: a systematic review and meta-analysis. Yuan L; Dai X; Yang M; Cai Q; Shao N Int J Chron Obstruct Pulmon Dis; 2016; 11():1477-83. PubMed ID: 27418821 [TBL] [Abstract][Full Text] [Related]
5. Effects of roflumilast in COPD patients receiving inhaled corticosteroid/long-acting β2-agonist fixed-dose combination: RE(2)SPOND rationale and study design. Rennard SI; Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Siddiqui S; Anzueto A; Zhu H Int J Chron Obstruct Pulmon Dis; 2016; 11():1921-8. PubMed ID: 27574416 [TBL] [Abstract][Full Text] [Related]
6. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Martinez FJ; Calverley PM; Goehring UM; Brose M; Fabbri LM; Rabe KF Lancet; 2015 Mar; 385(9971):857-66. PubMed ID: 25684586 [TBL] [Abstract][Full Text] [Related]
7. Roflumilast: a novel treatment for chronic obstructive pulmonary disease. Reid DJ; Pham NT Ann Pharmacother; 2012 Apr; 46(4):521-9. PubMed ID: 22433610 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of roflumilast in patients with chronic obstructive pulmonary disease: a systematic review and meta-analysis. Oba Y; Lone NA Ther Adv Respir Dis; 2013 Feb; 7(1):13-24. PubMed ID: 23197074 [TBL] [Abstract][Full Text] [Related]
9. Health status in patients with COPD treated with roflumilast: two large noninterventional real-life studies: DINO and DACOTA. Kardos P; Mokros I; Sauer R; Vogelmeier CF Int J Chron Obstruct Pulmon Dis; 2018; 13():1455-1468. PubMed ID: 29765213 [TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of roflumilast in patients with stable chronic obstructive pulmonary disease: a meta-analysis. Yan JH; Gu WJ; Pan L Pulm Pharmacol Ther; 2014 Feb; 27(1):83-9. PubMed ID: 23624309 [TBL] [Abstract][Full Text] [Related]
11. Pooled subpopulation analyses of the effects of roflumilast on exacerbations and lung function in COPD. Hanania NA; Calverley PM; Dransfield MT; Karpel JP; Brose M; Zhu H; Goehring UM; Rowe P Respir Med; 2014 Feb; 108(2):366-75. PubMed ID: 24120253 [TBL] [Abstract][Full Text] [Related]
12. Efficacy of roflumilast in the COPD frequent exacerbator phenotype. Wedzicha JA; Rabe KF; Martinez FJ; Bredenbröker D; Brose M; Goehring UM; Calverley PMA Chest; 2013 May; 143(5):1302-1311. PubMed ID: 23117188 [TBL] [Abstract][Full Text] [Related]
13. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting β2-Agonist on Chronic Obstructive Pulmonary Disease Exacerbations (RE(2)SPOND). A Randomized Clinical Trial. Martinez FJ; Rabe KF; Sethi S; Pizzichini E; McIvor A; Anzueto A; Alagappan VK; Siddiqui S; Rekeda L; Miller CJ; Zetterstrand S; Reisner C; Rennard SI Am J Respir Crit Care Med; 2016 Sep; 194(5):559-67. PubMed ID: 27585384 [TBL] [Abstract][Full Text] [Related]
14. Clinical Considerations for Roflumilast: A New Treatment for COPD. Kelly Freeman ML Consult Pharm; 2012 Mar; 27(3):189-93. PubMed ID: 22421519 [TBL] [Abstract][Full Text] [Related]
15. Roflumilast for the treatment of chronic obstructive pulmonary disease. Rabe KF Expert Rev Respir Med; 2010 Oct; 4(5):543-55. PubMed ID: 20649375 [TBL] [Abstract][Full Text] [Related]
18. Does roflumilast decrease exacerbations in severe COPD patients not controlled by inhaled combination therapy? The REACT study protocol. Calverley PM; Martinez FJ; Fabbri LM; Goehring UM; Rabe KF Int J Chron Obstruct Pulmon Dis; 2012; 7():375-82. PubMed ID: 22791991 [TBL] [Abstract][Full Text] [Related]
19. What is the role of roflumilast in chronic obstructive pulmonary disease? Lau C; Mehta AC; Hatipoglu U Cleve Clin J Med; 2017 Jan; 84(1):13-15. PubMed ID: 28084977 [No Abstract] [Full Text] [Related]
20. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary disease. Rabe KF Br J Pharmacol; 2011 May; 163(1):53-67. PubMed ID: 21232047 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]